OND.F · Oncopeptides AB (publ)

-

Please sign in to comment on OND.F

1 Comment

Admin

4 years ago

Oncopeptides AB (publ) is currently in a long term downtrend where the price is trading 50.5% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Oncopeptides AB (publ)'s total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 56.5% to $-383M since the same quarter in the previous year.

Finally, its free cash flow fell by 64.6% to $-357M since the same quarter in the previous year.

Based on the above factors, Oncopeptides AB (publ) gets an overall score of 1/5.

Exchange	F
CurrencyCode	EUR
ISIN	SE0009414576
Sector	Healthcare
Industry	Biotechnology

Market Cap	38M
PE Ratio	None
Target Price	None
Beta	-0.54
Dividend Yield	None

ABOUT

Oncopeptides AB (publ)

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden

OND.F · Oncopeptides AB (publ)

-

Oncopeptides AB (publ)

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Oncopeptides AB (publ) using a moving average strategy